Protein Kinase Inhibitors: all 15,038 studies that test it

Page 82 of 151. Open to participants first (2,480), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double ExpressionActive, not recruitingNCT05189197Phase 2
• Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1
• Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular MelanomaCompletedNCT05187884Phase 2
• A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid TumorsCompletedNCT05187858Phase 1
• Food Effect of VS-6766 in Healthy Adult SubjectsCompletedNCT05187169Phase 1
• (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisActive, not recruitingNCT05186753Phase 2
• Paxalisib With a High Fat, Low Carb Diet and Metformin for GlioblastomaCompletedNCT05183204Phase 2
• AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma PatientsActive, not recruitingNCT05182905Early Phase 1
• Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI ResistanceStatus unknownNCT05178511Phase 2
• A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy VolunteersCompletedNCT05178355Phase 1
• Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948TerminatedNCT05178342Phase 2
• Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLCTerminatedNCT05176925Phase 2
• A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult ParticipantsCompletedNCT05176873Phase 1
• HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHLWithdrawnNCT05176691Phase 1
• Avelumab, Palbociclib and Axitinib in Advanced RCCWithdrawnNCT05176288Phase 2
• Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast CancerTerminatedNCT05176080Phase 1/2
• Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/RearrangementsActive, not recruitingNCT05174650Phase 2
• A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid TumorsCompletedNCT05173142Phase 1/2
• Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckActive, not recruitingNCT05172258Phase 2
• Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor SamplesStatus unknownNCT05171439Phase 2
• Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma PatientsCompletedNCT05171335Phase 2
• Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCCStatus unknownNCT05171309Phase 2
• Binimetinib Plus Belinostat for Subjects With Metastatic Uveal MelanomaActive, not recruitingNCT05170334Phase 2
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05170204Phase 3
• A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)SuspendedNCT05168904Phase 1/2
• Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular CarcinomaStatus unknownNCT05166772Phase 2
• Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung CarcinomaStatus unknownNCT05165355Phase 2
• Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLCActive, not recruitingNCT05163249Phase 2
• Donafenib Plus Sintilimab for Advanced HCCCompletedNCT05162352Phase 2
• Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.CompletedNCT05162274Phase 1
• Roll-over Study to Allow Continued Access to RibociclibActive, not recruitingNCT05161195Phase 4
• Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular CarcinomaStatus unknownNCT05161143Phase 2
• Crizotinib Continuation Clinical StudyActive, not recruitingNCT05160922Phase 4
• A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200CompletedNCT05160389Phase 1
• Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male SubjectsCompletedNCT05159895Phase 1
• A Study of PRT2527 in Participants With Advanced Solid TumorsCompletedNCT05159518Phase 1
• Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCCCompletedNCT05156970Phase 2
• Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerActive, not recruitingNCT05156788Phase 2
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)Active, not recruitingNCT05156281Phase 3
• Neratinib Dose Escalation Regimen for HER2 Positive Early Breast CancerStatus unknownNCT05154396Phase 2
• Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.CompletedNCT05154201Phase 1/2
• Everolimus Trial in Laryngotracheal StenosisCompletedNCT05153668Early Phase 1
• (HARMONY) Study of BLU-701 in EGFR-mutant NSCLCTerminatedNCT05153408Phase 1
• Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.Status unknownNCT05153200Phase 4
• Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular LymphomaWithdrawnNCT05152459Phase 1/2
• A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaActive, not recruitingNCT05147558Phase 2
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)Active, not recruitingNCT05147220Phase 3
• Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR MutationCompletedNCT05146219Phase 2
• A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian CancerStatus unknownNCT05145218Phase 3
• Lorlatinib Continuation StudyActive, not recruitingNCT05144997Phase 4
• Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic PhaseActive, not recruitingNCT05143840Phase 2
• Alpelisib And Sacituzumab Govitecan For Treatment Of Breast CancerActive, not recruitingNCT05143229Phase 1
• Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine CarcinomasStatus unknownNCT05142865Phase 2
• Fruquintinib in the Treatment of Soft Tissue SarcomaStatus unknownNCT05142631Phase 2
• Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System TumorsStatus unknownNCT05139082Phase 1/2
• A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine RegimenStatus unknownNCT05138159Phase 2
• Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation SyndromeStatus unknownNCT05137496Phase 3
• AK105 Combined With Anlotinib in Patients With Cervical CancerActive, not recruitingNCT05137171Phase 2
• Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous NephropathyActive, not recruitingNCT05136456Phase 2
• Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic KeratosisActive, not recruitingNCT05136144Phase 2
• Combination of Capmatinib + Spartalizumab in Advanced Oesogastric AdenocarcinomaSuspendedNCT05135845Phase 2
• Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCCStatus unknownNCT05134532Phase 2
• A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory TrialStatus unknownNCT05133349Phase 2
• Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant TreatmentActive, not recruitingNCT05132790Not applicable
• Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular CarcinomaStatus unknownNCT05131698Early Phase 1
• Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.CompletedNCT05130515Phase 2
• A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal CancerStatus unknownNCT05130021Phase 2
• The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E MutationActive, not recruitingNCT05127759Phase 2
• Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative NeoplasmsTerminatedNCT05127174Phase 1
• A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid TumorsStatus unknownNCT05125523Phase 1
• Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)CompletedNCT05125471Phase 2
• Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaStatus unknownNCT05124431Phase 2
• An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail PsoriasisCompletedNCT05124080Early Phase 1
• A Study of Orelabrutinib in Patients With ITPStatus unknownNCT05124028Phase 1/2
• Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated CorticosteroidsTerminatedNCT05123040Phase 1/2
• A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial CarcinomaStatus unknownNCT05121363Phase 2
• Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus MethotrexateStatus unknownNCT05121298Phase 3
• Study of Ruxolitinib for Acute and Chronic Graft Versus Host DiseaseCompletedNCT05121142Phase 1
• A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain TumorsWithdrawnNCT05120960Phase 1
• A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionActive, not recruitingNCT05120349Phase 3
• Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) FormulationsCompletedNCT05118958Phase 1
• Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid TumorsStatus unknownNCT05118841Phase 1
• Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT StudyCompletedNCT05117957Phase 2
• Study of HA121-28 in Patients With Non-Small Cell Lung CancerStatus unknownNCT05117658Phase 2
• Phase 2 Study of 9-ING-41 With Chemotherapy in SarcomaWithdrawnNCT05116800Phase 2
• Sarcomas and DDR-Inhibition; a Combined Modality StudyTerminatedNCT05116254Phase 1
• Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid TumoursCompletedNCT05114668Phase 1
• A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 MutationStatus unknownNCT05114603Phase 2
• Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer PatientsActive, not recruitingNCT05114421Phase 2
• Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous AblativeActive, not recruitingNCT05113186Phase 2
• A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)CompletedNCT05112952Phase 1
• Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus unknownNCT05111444Phase 2
• TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After ResectionStatus unknownNCT05111366Phase 2
• A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid TumorsTerminatedNCT05109975Phase 1
• A Dose Escalation and Food Effect Study of SKLB1028 in Healthy SubjectsCompletedNCT05109663Phase 1
• Surufatinib in Patients With Osteosarcoma and Soft Tissue SarcomaActive, not recruitingNCT05106777Phase 2
• A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLCTerminatedNCT05106335Phase 3
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy ParticipantsCompletedNCT05105607Phase 1
• Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe AsthmaCompletedNCT05104892Phase 2
• Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT05104801Phase 2

← Protein Kinase Inhibitors overview